Findings

What do systematic reviews say?

Ignored "IF": search terms need at least 3 characters.

1,793 questions · 1,866 findings · 339 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 245 · 13.1%GRADE not reported 142 · 7.6%Very low 612 · 32.8%Low 513 · 27.5%Moderate 305 · 16.3%High 49 · 2.6%

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

2 findings from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.3 [0.93, 1.83]
2 studies · 461 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.04 [0.76, 1.43]
1 study · 459 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 2.33 [1.4, 3.86]
1 study · 70 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.32 [1.06, 1.64]
2 studies · 172 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.07 [0.92, 1.25]
2 studies · 257 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.44 [0.32, 0.6]
1 study · 124 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.37, 1.75]
2 studies · 173 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.45 [0.24, 0.84]
2 studies · 262 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.77 [0.55, 1.08]
2 studies · 461 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.78 [0.58, 1.06]
2 studies · 496 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ When compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.54, 1]
1 study · 677 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.34, 1.58]
1 study · 39 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

4 findings from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.64, 1.01]
1 study · 456 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.94 [0.44, 2.03]
2 studies · 206 participants
Moderate
Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.06 [0.83, 1.36]
1 study · 457 participants
Moderate

Show 1 more finding

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.9 [0.74, 1.11]
1 study · 677 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ dystonia ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 7.43 [1.07, 51.54]
1 study · 27 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 2.28 [1.67, 3.11]
1 study · 124 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Tremor · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ tremor… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 4.18 [1.1, 15.85]
1 study · 27 participants
Moderate

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with ultra low dose (<2 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.6 [0.37, 0.96]
2 studies · 459 participants
Moderate

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.29 [0.17, 0.52]
2 studies · 173 participants
Moderate

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.38 [0.81, 2.34]
2 studies · 496 participants
Moderate

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
1 study · 679 participants
Moderate

STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.75 [0.53, 1.08]
2 studies · 941 participants
Moderate